MediWound (MDWD) Share-based Compensation (2013 - 2026)
MediWound (MDWD) posted Share-based Compensation of $755000.0 for Q2 2026, up 17.24% on a QoQ basis from $644000.0 in Q1 2026, and down 12.41% year-over-year from $862000.0 in Q2 2025.
Powered by 
Analysis
MediWound (MDWD) Share-based Compensation (2013 - 2026) Analysis & Trends
MediWound has reported Share-based Compensation for 14 years, with the latest figure at $755000.0 in Q2 2026.
- On a quarterly basis, Share-based Compensation fell 12.41% year-over-year to $755000.0 in Q2 2026; TTM through Jun 2026 was $2.8 million, a 21.63% decrease from a year earlier, with the FY2025 full-year figure at $3.1 million, down 0.96% from the prior year.
- Share-based Compensation was $755000.0 for Q2 2026 at MediWound, up from $644000.0 in the prior quarter.
- The five-year high for Share-based Compensation was $1.0 million in Q3 2024, with the low at $252000.0 in Q2 2022.
- Average Share-based Compensation over 5 years is $640611.1, with a median of $684500.0 recorded in 2022.
- The sharpest annual moves came in 2023 and 2024: Share-based Compensation plunged 56.01% in 2023, then soared 236.33% in 2024.
- Over 5 years, Share-based Compensation stood at $642000.0 in 2022, then slumped by 53.58% to $298000.0 in 2023, then jumped by 175.84% to $822000.0 in 2024, then dropped by 19.46% to $662000.0 in 2025, then grew by 14.05% to $755000.0 in 2026.
- The last three Share-based Compensation figures came in at $755000.0 (Q2 2026), $644000.0 (Q1 2026), and $662000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 247.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 231.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 108.10 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 243.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 120.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 77.40 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 83.34 Mn |
| 10 | MediWound | 156.09 Mn | 120.75 Mn | 337,000.00 | 755,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 755,000.00 |
| Mar 31, 2026 | 644,000.00 |
| Dec 31, 2025 | 662,000.00 |
| Sep 30, 2025 | 740,000.00 |
| Jun 30, 2025 | 862,000.00 |
| Mar 31, 2025 | 844,000.00 |
| Dec 31, 2024 | 822,000.00 |
| Sep 30, 2024 | 1.05 Mn |
| Jun 30, 2024 | 758,000.00 |
| Mar 31, 2024 | 512,000.00 |
| Dec 31, 2023 | 298,000.00 |
| Sep 30, 2023 | 311,000.00 |
| Jun 30, 2023 | 712,000.00 |
| Mar 31, 2023 | 619,000.00 |
| Dec 31, 2022 | 642,000.00 |
| Sep 30, 2022 | 707,000.00 |
| Jun 30, 2022 | 252,000.00 |
| Mar 31, 2022 | 345,000.00 |
| Dec 31, 2021 | 390,000.00 |
| Sep 30, 2021 | 399,000.00 |